Welcome to our dedicated page for Pulsenmore Ltd. SEC filings (Ticker: PLSM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Pulsenmore Ltd.'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Pulsenmore Ltd.'s regulatory disclosures and financial reporting.
Pulsenmore Ltd. (PLSM) reported that its home-use ultrasound technology will be integrated into the Lis Maternity and Women’s Hospital at Ichilov, a major Israeli women’s and maternity care center, expanding the use of at-home pregnancy monitoring.
The addition of Lis strengthens Pulsenmore’s presence in central Israel and broadens access to its hybrid care model, which combines hospital or clinic monitoring with certain ultrasound scans performed at home for eligible patients under medical guidance. Pulsenmore’s activities in Israel now span three integration models: a nationwide service with Clalit Health Services, a Hospital at Home model used in several hospitals, and a hybrid model for high-risk pregnancies that mixes hospital-based and at-home examinations.
The company states that these models are designed to let pregnant women continue part of their monitoring in a home environment while remaining under their care team’s supervision, which may be particularly valuable for women requiring frequent monitoring who live far from medical centers. Pulsenmore also reiterates standard forward-looking statement cautions regarding the commercial potential and operational and regulatory risks around its expansion.
Pulsenmore Ltd. reported that the Israel Innovation Authority approved a $1.27 million grant for its SmartScan AI research and development program. Over the past month, total approved AI grants for Pulsenmore reached approximately $1.6 million, supporting two programs with a combined R&D scope of about $3.12 million.
The 12‑month SmartScan AI program aims to develop AI-powered, real-time guidance for home ultrasound, reducing dependence on user skill and enabling clinicians to handle a higher volume of remote examinations. Development will leverage data from more than 250,000 clinical scans and focus on fast, on-device processing using Edge AI.
Pulsenmore Ltd. reports that shareholders held the 2026 Annual General Meeting of Shareholders on August 6, 2026. At this meeting, shareholders approved all six proposals that were presented, each in accordance with the required majority.
The approved proposals correspond to those described in the Notice of Annual General Meeting of Shareholders dated July 1, 2026, which had been furnished to the U.S. Securities and Exchange Commission as an exhibit to a prior Form 6-K.
Pulsenmore Ltd. has filed a resale prospectus covering up to 3,125,000 ordinary shares for sale by a single selling shareholder. These shares are issuable upon exercise of warrants sold in a June 2026 private placement, including 1,562,500 shares from pre-funded warrants and 1,562,500 shares from ordinary warrants.
The company will not receive proceeds from any resale of shares, but could receive up to approximately $7.5 million if all warrants are exercised for cash. Ordinary shares outstanding were 6,502,844 as of July 1, 2026. The filing highlights potential dilution, share price volatility, and significant geopolitical risks tied to operating from Israel, alongside Pulsenmore’s commercialization of its home ultrasound devices (ES, FC, MC) in multiple international markets.
Pulsenmore Ltd. reports that it has been selected for Israel’s Healthcare AI Regulatory Sandbox Program, established by the Israel Innovation Authority and the Ministry of Health, to lead a $1 million AI development project.
The project supports development and clinical validation of AI applications that improve workflow efficiency and scalability of Pulsenmore’s home ultrasound platform for pregnant women. The platform connects a home-use ultrasound device to a smartphone, transmitting scans for physician review, and has been used in more than 250,000 home ultrasound scans with partners including Clalit Health Services and other organizations worldwide.
New AI tools are intended to automatically identify key ultrasound parameters and present findings to physicians, aiming to reduce review time, speed results, and expand clinician capacity. Pulsenmore will collaborate with Beilinson Hospital on development and clinical validation of these AI applications within the government-backed regulatory framework.
Pulsenmore Ltd., a health care biotechnology company incorporated in Israel, reported an exempt securities offering under Rule 506(b) of Regulation D.
The company sold $7,500,000 of securities consisting of 1,562,500 pre-funded warrants and 1,562,500 ordinary warrants at $4.7999 per pre-funded warrant and accompanying ordinary warrant.
A.G.P./Alliance Global Partners acted as placement agent and received $50,000 in accountable out-of-pocket legal expenses. Pulsenmore plans to use the net proceeds for marketing and commercialization activities, working capital and other general corporate purposes.
Pulsenmore Ltd. is registering for resale up to 3,125,000 ordinary shares issuable upon exercise of warrants issued in a June 2026 private placement.
The prospectus states the offering is a resale by the selling shareholder Armistice Capital Master Fund Ltd., that the company will not receive proceeds from resale transactions, and that the company may receive proceeds only if the warrants are exercised for cash. The offering is conditioned on the registration statement becoming effective.
Pulsenmore Ltd. has called its Annual General Meeting for August 6, 2026 in Ramat Gan, Israel. Shareholders will vote on re-electing Class I directors Rachel Guz‑Lavi and Hagai Itkin, a 2026 cash bonus plan for CEO and controlling shareholder Dr. Elazar Sonnenschein, and payment of the discretionary portions of 2025 bonuses to Dr. Sonnenschein (about $22,500) and VP R&D Menashe Sonnenschein (about $3,500).
Investors are also asked to approve a Revised Amended and Restated Compensation Policy that tightens pay caps and adds an overall annual cost ceiling per officer, and to re-appoint PwC as independent auditor for 2026. The filing outlines voting mechanics, special majority rules for related‑party items, and current ownership, with 6,502,844 ordinary shares outstanding as of June 29, 2026.
Pulsenmore Ltd. reports that it has cancelled its previously scheduled Annual General Meeting of Shareholders that was to be held on July 9, 2026 at 10:00 a.m. (Israel time) in Ramat Gan, Israel.
The meeting is being cancelled so the company can revise Proposal 5, which concerns approval of its Amended and Restated Compensation Policy. These revisions follow discussions with certain shareholders and are intended to reflect their feedback. Pulsenmore plans to call a new annual meeting and will furnish a new report with revised proxy materials, including an updated compensation policy and related documents.